This Month in Psychopharmacology

Browsing articles in "Psychotic Disorders"

Recall: Paliperidone Extended-Release Tablets
June 16, 2017

Teva Pharmaceuticals has issued a voluntary recall of a single lot of paliperidone extended-release tablets...

Continue reading (Members only)

Highlights from the 2017 APA Annual Meeting
June 8, 2017

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.

2-Month Dose of Injectable Atypical Antipsychotic Approved
June 6, 2017

The U.S. Food and Drug Administration (FDA) has approved a new 2-month dose of an extended-release injectable atypical antipsychotic...

Continue reading (Members only)

No Evidence for Negative Long-Term Effect of Antipsychotic Treatment in Schizophrenia
May 17, 2017

Although antipsychotics have established efficacy for the acute control of positive symptoms of psychosis, there has been concern that the long-term use of these agents may have negative neurological consequences, such as reduced brain volume and sensitization of dopamine receptors...

Continue reading (Members only)

Death Rate in Youth With First-Episode Psychosis Is Higher Than Previously Thought
April 14, 2017

New research funded by the National Institute of Mental Health (NIMH) shows that young people experiencing a first episode of psychosis have a mortality rate that is 24 times that of the general population during the first year after initial diagnosis...

First Drug Approved to Treat Tardive Dyskinesia
April 12, 2017

The U.S. Food and Drug Administration (FDA) has approved valbenazine, trade name Ingrezza, for the treatment of tardive dyskinesia...

FDA Update: New Warning Added to Antipsychotic Labels
April 6, 2017

The U.S. Food and Drug Administration (FDA) has approved a labeling update for all antipsychotic medications adding a new warning to the prescribing information....

Continue reading (Members only)

Diabetes Risk is Increased in First-Episode Schizophrenia
January 27, 2017

Epidemiologic studies have established that patients with schizophrenia live 15-30 years less than the general public, for reasons not related to the central nervous system, but to cardiovascular health consequences. The rate of type 2 diabetes is estimated to be 2-3 times higher (10-15%) in schizophrenia than the general population...

Continue reading (Members only)

New Study Does Not Find That Omega-3 Fatty Acids Reduce Transition to Psychosis
January 6, 2017

A multicenter, randomized clinical trial failed to replicate previous findings that omega-3 fatty acids reduce the transition to psychosis in young people at ultrahigh risk for psychotic disorders...

Continue reading (Members only)

Neurocognitive Function and Risk of Psychosis Conversion: NAPLS-2 Data
November 11, 2016

Neurocognitive dysfunction is a hallmark feature of schizophrenia. Identifying the severity and pattern of neurocognitive dysfunction during the “near-psychotic”, clinical high-risk (CHR) state of psychosis is necessary for developing more effective and preventive treatments...

Continue reading (Members only)

Top of Page